Skip to main content

Table 3 Changes in markers of bone metabolism and hip BMD during the observation period

From: Clinical advantage and tolerability of ibandronate in hemodialysis patients: a retrospective study

  Baseline End of study P*
TRACP-5b (mU/dL) 785.3 ± 385.8 638.2 ± 423.4 0.03
BALP (μg/L) 18.1 ± 11.4 17.4 ± 10.3 0.55
Hip BMD (g/cm2), n = 9 0.51 ± 0.10 0.47 ± 0.11 0.07
  1. Values represent mean ± standard deviation
  2. TRACP-5b tartrate-resistant acid phosphatase-5b, BALP bone-specific alkaline phosphatase, BMD bone mineral density
  3. *Paired t test (P < 0.05)